EP
TNXP icon

Essential Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Essential Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96K Buy
+506
New +$7.79K ﹤0.01% 1420

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Essential Partners's TNXP Position: Q1 2026 in Review

Essential Partners opened a new position in Tonix Pharmaceuticals (TNXP) in Q1 2026: 506 shares worth $6.96K. The stake represents ﹤0.01% of the portfolio and ranks #1420 among its holdings.

81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Essential Partners held 506 shares of Tonix Pharmaceuticals worth $6.96K as of Q1 2026.
  • Tonix Pharmaceuticals was a new Essential Partners position in Q1 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q1 2026, its #1420 holding.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.